Anti-CD133 monoclonal antibody (Ab)-conjugated poly(lactide-co-glycolide) (PLGA) nanocarriers, for the targeted delivery of oxaliplatin (OXA) and superparamagnetic nanoparticles (IO-OA) to colorectal cancer cells (CaCo-2), were designed, synthesized, characterized, and evaluated in this study. The co-encapsulation of OXA and IO-OA was achieved in two types of polymeric carriers, namely, PLGA and poly(lactide-co-glycolide)-poly(ethylene glycol) (PLGA-PEG) by double emulsion. PLGA_IO-OA_OXA and PEGylated PLGA_IO-OA_OXA nanoparticles displayed a comparable mean diameter of 207 ± 70 nm and 185 ± 119 nm, respectively. The concentration of the released OXA from the PEGylated PLGA_IO-OA_OXA increased very rapidly, reaching ~100% release after only 2 h, while the PLGA_IO-OA_OXA displayed a slower and sustained drug release. Therefore, for a controlled OXA release, non-PEGylated PLGA nanoparticles were more convenient. Interestingly, preservation of the superparamagnetic behavior of the IO-OA, without magnetic hysteresis all along the dissolution process, was observed. The non-PEGylated nanoparticles (PLGA_OXA, PLGA_IO-OA_OXA) were selected for the anti-CD133 Ab conjugation. The affinity of Ab-coated nanoparticles for CD133-positive cells was examined using fluorescence microscopy in CaCo-2 cells, which was followed by a viability assay.
- MeSH
- antigen AC133 imunologie MeSH
- antitumorózní látky chemie MeSH
- imunokonjugáty farmakologie MeSH
- kolorektální nádory farmakoterapie imunologie patologie MeSH
- kopolymer kyseliny glykolové a mléčné chemie MeSH
- lidé MeSH
- monoklonální protilátky chemie MeSH
- nanočástice aplikace a dávkování chemie MeSH
- nosiče léků chemie MeSH
- oxaliplatin chemie MeSH
- systémy cílené aplikace léků * MeSH
- uvolňování léčiv MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
The aim of this study was to develop a method for the separation of oxaliplatin enantiomers at attomolar concentration levels. A combination of capillary electrophoresis and inductively coupled plasma mass spectrometry was chosen due to their unique characteristics, including fast and easy modification of separation selectivity, and significant limits of detection and linearity. In the first step, we optimized conditions for the separation of oxaliplatin enantiomers including background electrolyte composition and concentration, pH, and type and concentration of the chiral selector. Under optimal conditions, sodium borate buffer pH 9.5, ionic strength 40 mmol L-1, with 60 mg mL-1 sulfated β-cyclodextrin, separation was obtained with a resolution of 2.0. This electrolyte system was then used in the 'in-house' connection of capillary electrophoresis with inductively coupled plasma mass spectrometer. In this instance, separation lasted for 9.5 min. Calibrations were linear in the range of 0.1-500 μg mL-1 with R2 of 0.9999. LOD and LOQ values were of 64 ng mL-1 and 116 ng mL-1 of oxaliplatin, respectively. This represents detection of 49 fg or 125 attomol of oxaliplatin enantiomers in the capillary electrophoresis injected sample zone. Finally, the method was successfully applied for detection of oxaliplatin enantiomers in spiked urine samples.